Does Medicaid Cover Wegovy in Michigan? Who Qualifies and Costs

Michigan Medicaid does cover Wegovy, but as of January 1, 2026, coverage for weight-loss use is limited to beneficiaries with severe obesity who have already tried and failed other anti-obesity medications and whose prescriber confirms the drug is being used to avoid bariatric surgery. Coverage is broader when Wegovy is prescribed for a non-obesity condition such as cardiovascular disease or severe liver disease.

Who Qualifies for Wegovy as a Weight-Loss Drug

To get Wegovy approved for obesity under Michigan Medicaid, a beneficiary has to meet all three of these criteria:

A body mass index of 40 or higher.¹
Documented trial and failure of all other clinically appropriate weight-loss interventions, including the preferred anti-obesity medications on the state formulary.²
A physician attestation that the medication is being used specifically to avoid the need for higher-cost bariatric surgery.¹

All three have to be documented. Missing any one of them will result in a denial for the obesity indication.

What “Tried and Failed” Means

The step-therapy requirement is not a formality. Under the prior authorization criteria updated June 1, 2026, prescribers have to show that the patient tried and failed treatment with medications in five categories: benzphetamine, diethylpropion, orlistat products, phendimetrazine, and phentermine products. Qsymia, a combination of phentermine and topiramate, is also on the preferred list that must be tried first.³ Each of these preferred drugs is cheaper than Wegovy, and each one carries its own prior authorization.¹

Authorizations run for six months. To renew, adults have to show at least a 5% loss of body weight since the last approval. Patients ages 12 to 17 have to show that their BMI has held steady or improved based on CDC growth charts.³

When Wegovy Is Prescribed for Something Other Than Obesity

The tightened rules only apply when Wegovy is prescribed solely for weight loss. Coverage for other FDA-approved uses of the drug is governed by separate, less restrictive criteria that did not change on January 1.²

Wegovy remains covered for beneficiaries who are overweight or obese and have established cardiovascular disease, and for those with severe liver disease. The Michigan Medicaid formulary revised in March 2026 lists distinct clinical criteria sections for Wegovy’s cardiovascular risk reduction indication and for metabolic dysfunction-associated steatohepatitis, treating each as its own coverage pathway.⁴ GLP-1 drugs prescribed for type 2 diabetes, such as Ozempic and Mounjaro, are not affected at all.⁵

What You’ll Pay at the Pharmacy

Wegovy was moved to non-preferred status on the state’s Single Preferred Drug List. For beneficiaries who are not enrolled in a Medicaid Health Plan and are not exempt from copayments, the copay rose from $1 to $3 per prescription.²

Which Michigan Medicaid Members Are Affected

The rules apply the same way to everyone on Michigan Medicaid. That includes traditional Medicaid, the Healthy Michigan Plan (the state’s Medicaid expansion), fee-for-service coverage, and managed care enrollees.⁶⁷ There are no separate rules or carve-outs for particular populations.

If Your Wegovy Prescription Is Denied

You have appeal rights, and the path depends on whether you’re in a Medicaid Health Plan or fee-for-service.

Managed care members start with an internal plan appeal. Molina Healthcare, for example, requires appeals to be filed within 60 calendar days of the denial. A healthcare professional not involved in the original decision reviews the case, and a written decision comes within 30 calendar days. If you file within 10 calendar days of the denial notice and the appeal involves cutting off or reducing a treatment that was previously authorized, you can ask for your benefits to continue during the appeal.⁸

If the internal appeal doesn’t succeed, you can request a State Fair Hearing through MDHHS. Hearing requests go on the department’s standard form and can be filed at a local DHHS office or faxed to the state.⁹ The Health Insurance Consumer Assistance Program (HICAP) offers free help with disputes at (877) 999-6442.⁸

Why the Rules Got Stricter

The changes came from the state budget. Michigan Medicaid spent more than $409 million on GLP-1 drugs in fiscal year 2024 before manufacturer rebates, and the number of beneficiaries taking them climbed from about 20,935 in fiscal year 2021 to 90,324 in 2024.¹⁰

The fiscal year 2026 budget, Public Act 22 of 2025, cut $240 million from GLP-1 pharmaceutical appropriations and directed MDHHS to tighten the criteria for weight-loss prescribing. The department formalized the new rules in provider notice Numbered Letter L 25-73, dated December 8, 2025, with the restrictions taking effect January 1, 2026.²¹⁰

1
University of Michigan Medicine. Expert Q&A: Michigan Medicaid’s New Limits on GLP-1 Weight Management Medications
2
Michigan.gov. Numbered Letter L 25-73 – Update of Pharmacy Drug Coverage for Treatment of Obesity
3
Upper Peninsula Health Plan. Medicaid Benefit Non-Part D Prior Authorization Criteria
4
Prime Therapeutics. Michigan Medicaid Clinical and PDL PA Criteria
5
Bridge Michigan. Michigan Limits Access to Weight Loss Drugs for Medicaid Patients
6
Priority Health. Medicaid GLP-1 Coverage Changes Effective Jan. 1, 2026
7
Meridian Health Plan. GLP-1 Benefit Reduction Bulletin
8
Molina Healthcare. Adverse Benefit Determination and Appeals
9
Washtenaw Health Project. Medicaid Appeals Part 1: Filing a Hearing
10
Michigan Public. Michigan Cuts Off Weight Loss Drugs for Most Medicaid Patients, Saving $240 Million